Drug · DIN 02302845
EXELON PATCH 5
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 26, 2022; first marketed December 12, 2007.
- Drug Identification Number (DIN)
- 02302845
- Company (DIN owner)
- Knight Therapeutics Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Patch
- Route
- Transdermal
- Therapeutic class (ATC)
- Rivastigmine N06DA03
- Class
- Human
- Record last updated
- July 30, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RIVASTIGMINE | 4.6 MG | 24 HOUR |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 3, 2022: NOC 29131New Drug Submission (NDS) · Administrative: Change in Product Ownership
- November 29, 2007: NOC 9209New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “exelon”. A notice may cover another product or only some lots: read it to see what it covers.